Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure

Current Medical Research and Opinion

Volumn 23, Issue 4, 2007, Pages 683-689

  Arcieri, Enyr S ^a,b   Arcieri, Rafael S ^b   Pereira, Ana C A ^c   Andreo, Eduardo G V ^b   Finotti, Ioná G A ^b   Sá Filho, Wanderley F ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF UBERLÂNDIA   (Brazil)

^c Sociedade Beneficiente Santa Casa de Campo Grande   (Brazil)

Author keywords

Fixed combination; Glaucoma; Ocular hypertension; Therapy

Indexed keywords

BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; TIMOLOL; TRAVOPROST;

ADULT; AGED; ARTICLE; BLURRED VISION; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EYE BURN; EYE BURNING; EYE DISCHARGE; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; LACRIMATION; MALE; MULTICENTER STUDY; OPEN ANGLE GLAUCOMA; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT OUTCOME;

AGED; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INSTILLATION, DRUG; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; QUINOXALINES; SULFONAMIDES; THIOPHENES; TIMOLOL;

EID: 34247502868     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X178694     Document Type: Article

References (30)

1. Alward WL. Medical management of glaucoma. N Engl J Med 1998;339:1298-307
2. Stewart WC, Sharpe ED, Harbin TS Jr, et al. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure. Am J Ophthalmol 2000;129:723-7
3. Francis BA, Du LT, Berke S, et al. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0.5% timolol - a randomized controlled trial and a replacement study. J Clin Pharm Ther 2004;29:375-80
4. Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol 1998;82:1249-53
5. Sall KN, Greff LJ, Johnson-Pratt LR, et al. Dorzolamide/timolol combination versus concomitant administration of brimonidine and timolol: six-month comparison of efficacy and tolerability. Ophthalmology 2003;110:615-24
6. Zeyen T. Target pressures in glaucoma. Bull Sot Beige Ophtalmol 1999;274:61-5
7. Alm A, Widengard I, Kjellgren D, et al. Latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol. Br J Ophthalmol 1995;79:12-6
8. Kass MA, Hodapp E, Gordon M, et al. Part I. Patient administration of eyedrops: interview. Ann Ophthalmol 1982;14:775-9
9. Kass MA, Hodapp E, Gordon M, et al. Patient administration of eyedrops: observation. Part II. Ann Ophthalmol 1982;14:889-93
10. Cvenkel B, Inar A. Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002;216:175-9
11. Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv Ther 2001;18:205-15
12. Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998;105:1945-51
13. Strahlman E, Tipping R, Vogel R, International Dorzolamide Study Group. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. Arch Ophthalmol 1995;113:1009-16
14. Wilkerson M, Cyrlin M, Lippa EA, et al. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch Ophthalmol 1993;111:1343-50
15. Rusk C, Sharpe E, Laurence J, et al. Dorzolamide Comparison Study Group. Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Clin Ther 1998;20:454-66
16. O'Donoghue EP, UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Br J Ophthalmol 2000;84:579-82
17. Araie M, Kitazawa Y, Azuma I, et al. The efficacy and safety of dose escalation of dorzolamide used in combination with other topical antiglaucoma agents. J Ocul Pharmacol Ther 2003;19:517-25
18. Sharpe ED, Day DG, Beischel CJ, et al. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension. Br J Ophthalmol 2004;88:953-6
19. Kampik A, Arias-Puente A, O'Brart DP, et al. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma 2002,11:90-6
20. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol 1996;41(Suppl):S27-37
21. DuBiner HB, Mroz M, Shapiro AM, et al. Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 2001;23:1969-83
22. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol 1996;41(Suppl):S19-26
23. Nordland JR, Pasaquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine. Arch Ophthalmol 1995;113:77-83
24. Whitson JT, Henry C, Hughes B, et al. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension. J Glaucoma 2004;13:168-73
25. Wang RF, Serle JB, Gagliuso DJ, et al. Comparison of the ocular hypotensive effect of brimonidine, dorzolamide, latanoprost, or artificial tears added to timolol in glaucomatous monkey eyes. J Glaucoma 2000;9:458-62
26. Carrasco Font C, Arias Puente A, Garcia Saenz MC, et al. Efficiency of brimonidine 0.2% and dorzolamide 2% as adjunctive therapy to beta-blockers [in Spanish]. Arch Soc Esp Oftalmol 2004;79:163-8
27. Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1999;106(Suppl):1-9
28. Craven ER, Walters TR, Williams R, et al. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2005;21:337-48
29. Goñi FJ. The Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol 2005;15:581-90
30. Solish AM, DeLucca PT, Cassel DA, et al. Dorzolamide/timolol fixed combination versus concomitant administration of brimonidine and timolol in patients with elevated intraocular pressure: a 3-month comparison of efficacy, tolerability, and patient-reported measures. J Glaucoma 2004;13:149-57